ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Echazarreta, A.
Right arrow Articles by Rodriguez-Roisin, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Echazarreta, A.
Right arrow Articles by Rodriguez-Roisin, R
Eur Respir J 1999; 14: 616-621
Copyright © ERS Journals Ltd 1999


Clinical Trial

Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma

AL Echazarreta, FP Gomez, J Ribas, M Achaval, JA Barbera, J Roca, KF Chung, and R Rodriguez-Roisin

Furosemide (Fur) may have an anti-inflammatory effect on airways in patients with asthma although its intrinsic mechanism remains elusive. Platelet-activating factor (PAF) is a potent proinflammatory mediator that induces systemic and respiratory effects in normal control subjects and asthmatics. The aim of this study was to assess whether pretreatment with nebulized Fur (40 mg) was able to modulate PAF-induced systemic and respiratory effects in asthma. Eleven patients were studied (mean+/-sem 22+/-0.8 yrs) with mild asthma (forced expiratory volume in one second, 95+/-4%) in a randomized, double-blind, placebo-controlled, cross-over fashion, one week apart. PAF challenge (18 microg) was carried out 15 min after administration of Fur or placebo. Peripheral blood neutrophils, respiratory system resistance, and arterial blood gases were measured at baseline, and 5, 15 and 45 min after PAF; urinary cysteinyl leukotriene E4 (uLTE4) was also measured, at baseline and 120 min after PAF challenge. Although Fur did not alter PAF-induced systemic and respiratory effects, it did partially inhibit (63%; p<0.04) the increments of uLTE4 levels shown after PAF inhalation. It is concluded that furosemide is not effective in protecting against platelet-activating factor challenge in patients with asthma despite its potential inhibition of leukotriene synthesis. These findings reinforce the view that the pulmonary effects of platelet-activating factor are mediated through different pathways.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
A. K Verma, J. H da Silva, and D. R Kuhl
Diuretic Effects of Subcutaneous Furosemide in Human Volunteers: A Randomized Pilot Study
Ann. Pharmacother., April 1, 2004; 38(4): 544 - 549.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin
Formoterol protects against platelet-activating factor-induced effects in asthma
Eur. Respir. J., January 1, 2004; 23(1): 71 - 75.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.